A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

Carcinoma, Hepatocellular Clinical Trial

— THBC002  

Official title:

Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00440934
• Other study ID #: THBC 002
• Status: Terminated
• Phase: Phase 2
• First received: February 24, 2007
• Last updated: May 2, 2008
• Start date: February 2007
• Est. completion date: December 2007

Study information

• Verified date: May 2008
• Source: Pasche, Boris, M.D.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Laws and standards
• Study type: Interventional

Clinical Trial Summary

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Phase I data suggest that low levels of electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of frequencies.

Description:

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Therapies for hepatocarcinoma are limited. Resection of the primary tumor is the therapeutic approach of first choice when possible. Although this intervention results in long-term survival for some patients, only a minority of them are surgical candidates because of limitations due to tumor size, patient's overall condition or presence of hepatic cirrhosis.

Phase I data suggest that low levels of amplitude-modulated electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of HCC-specific frequencies.

The patients will be offered ambulatory treatment, which will be administered three times a day for 60 min until disease progression or death.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• The patients must have a diagnosis of inoperable hepatocellular carcinoma.

• The patients who have an AFP level higher than 400 ng/ml and an appearance characteristic of cancer of the liver do not need histological confirmation. These patients must however have a negative serology for the antigen of surface of hepatitis B If serology for this antigen is positive, they must have a rate of AFP higher than 4000 ng/ml.

• Presence of one or more lesions measurable(s) according to criteria's RECIST.

Exclusion Criteria:

• Other anti-cancer treatments are not authorized during this study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular

Intervention

Device:
• Amplitude-modulated electromagnetic fields

Locations

Country	Name	City	State
Switzerland	Cabinet Médical de l'Avenue de la gare 6	Lausanne	Vaud

Sponsors (2)

Lead Sponsor	Collaborator
Pasche, Boris, M.D.	Barbault, Alexandre, M.S.

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	• To determine disease free survival at 4 months while receiving the experimental treatment.		4 months	No
Primary	Response rate		six months	No
Secondary	To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients.		six months	No